Parabilis Medicines, Inc. Stock Analysis & AI Score
Parabilis Medicines, Inc. (PBLS) has an ST Score of 63.4 (B), driven by its Profitability (A) and held back by its Valuation (C). PBLS last traded at $32.47.
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Parabilis Medicines, Inc. (PBLS) has an ST Score of 63.4 (B), driven by its Profitability (A) and held back by its Valuation (C). PBLS last traded at $32.47.
- Strongest
- ProfitabilityA
- Weakest
- ValuationC
All factor grades
- ProfitabilityA
- MomentumA-
- Financial StrengthB
- ForecastB-
- GrowthC+
- ValuationC
Contact
PBLS stock: frequently asked questions
What is PBLS's ST Score?
Parabilis Medicines, Inc. (PBLS) has an ST Score of 63.4 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PBLS a buy, hold, or sell?
Our ST Score grades it B (63.4/100). The ST Score is a data-driven signal, not a recommendation.
What are PBLS's factor grades?
Valuation C, Profitability A, Financial Strength B, Momentum A-, Growth C+, Forecast B-.
What is PBLS's valuation grade?
Parabilis Medicines, Inc. (PBLS) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PBLS's growth grade?
Parabilis Medicines, Inc. (PBLS) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PBLS's profitability grade?
Parabilis Medicines, Inc. (PBLS) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PBLS's financial strength grade?
Parabilis Medicines, Inc. (PBLS) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PBLS?
The average analyst price target for Parabilis Medicines, Inc. (PBLS) is $40.00, which is +23.2% versus the recent price of $32.47.